common.study.topics.clinical

Testing Experimental Treatment for Psoriatic Arthritis

common.study.values.description

A Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects With Psoriatic Arthritis

This is a Phase 4, multicenter, single-arm, open-label study to evaluate the impact of apremilast, either in monotherapy or with stable Methotrexate (MTX), on Magnetic resonance imaging (MRI) outcomes in subjects with active PsA with up to 5 years of disease duration (since diagnosis).

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - CC-10004

CC-10004

participant.views.study.view.additional

participant.views.study.view.scientific-title

A PHASE 4, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE IMPACT OF APREMILAST (CC-10004) MONOTHERAPY ON MRI OUTCOMES IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS

common.study.values.clinical-trial-id

NCT03783026

participant.views.study.view.id

dG6Qyb